Outcome of COVID-19 in Patients With Autoimmune Hepatitis: An International Multicenter Study

Cumali Efe, Renumathy Dhanasekaran, Craig Lammert, Berat Ebik, Fatima Higuera-de la Tijera, Costica Aloman, Ali Rıza Calışkan, Mirta Peralta, Alessio Gerussi, Hatef Massoumi, Andreea M. Catana, Murat Torgutalp, Tugrul Purnak, Cristina Rigamonti, Andres Jose Gomez Aldana, Nidah Khakoo, Hüseyin Kacmaz, Leyla Nazal, Shalom Frager, Nurhan DemirKader Irak, Zeynep Melekoğlu Ellik, Yasemin Balaban, Kadri Atay, Fatih Eren, Laura Cristoferi, Ersin Batıbay, Álvaro Urzua, Romee Snijders, Murat Kıyıcı, Murat Akyıldız, Nazım Ekin, Rotonya M. Carr, Murat Harputluoğlu, Ibrahim Hatemi, Manuel Mendizabal, Marcelo Silva, Ramazan Idilman, Marina Silveira, Joost P.H. Drenth, David N. Assis, Einar Björnsson, James L. Boyer, Pietro Invernizzi, Chyntia Levy, Thomas D. Schiano, Ezequiel Ridruejo, Staffan Wahlin

Research output: Contribution to journalArticlepeer-review

10 Scopus citations

Abstract

Background and Aims: Data regarding outcome of COVID-19 in patients with autoimmune hepatitis (AIH) are lacking. Approach and Results: We performed a retrospective study on patients with AIH and COVID-19 from 34 centers in Europe and the Americas. We analyzed factors associated with severe COVID-19 outcomes, defined as the need for mechanical ventilation, intensive care admission, and/or death. The outcomes of patients with AIH were compared to a propensity score–matched cohort of patients without AIH but with chronic liver diseases (CLD) and COVID-19. The frequency and clinical significance of new-onset liver injury (alanine aminotransferase > 2 × the upper limit of normal) during COVID-19 was also evaluated. We included 110 patients with AIH (80% female) with a median age of 49 (range, 18-85) years at COVID-19 diagnosis. New-onset liver injury was observed in 37.1% (33/89) of the patients. Use of antivirals was associated with liver injury (P = 0.041; OR, 3.36; 95% CI, 1.05-10.78), while continued immunosuppression during COVID-19 was associated with a lower rate of liver injury (P = 0.009; OR, 0.26; 95% CI, 0.09-0.71). The rates of severe COVID-19 (15.5% versus 20.2%, P = 0.231) and all-cause mortality (10% versus 11.5%, P = 0.852) were not different between AIH and non-AIH CLD. Cirrhosis was an independent predictor of severe COVID-19 in patients with AIH (P < 0.001; OR, 17.46; 95% CI, 4.22-72.13). Continuation of immunosuppression or presence of liver injury during COVID-19 was not associated with severe COVID-19. Conclusions: This international, multicenter study reveals that patients with AIH were not at risk for worse outcomes with COVID-19 than other causes of CLD. Cirrhosis was the strongest predictor for severe COVID-19 in patients with AIH. Maintenance of immunosuppression during COVID-19 was not associated with increased risk for severe COVID-19 but did lower the risk for new-onset liver injury during COVID-19.

Original languageEnglish (US)
Pages (from-to)2099-2109
Number of pages11
JournalHepatology
Volume73
Issue number6
DOIs
StatePublished - Jun 2021
Externally publishedYes

ASJC Scopus subject areas

  • Hepatology

Fingerprint

Dive into the research topics of 'Outcome of COVID-19 in Patients With Autoimmune Hepatitis: An International Multicenter Study'. Together they form a unique fingerprint.

Cite this